TickerTalks
Browse all tickers →
TickerTalks›$HYFT
HYHYFT

MindWalk Holdings Corp.

$HYFT·$67M·Biotechnology·Healthcare
$1.46+3.5%YTD-21.7%1Y-16.1%
Mentions · last 7 days
2026-07-10: 4 posts2026-07-11: 2 posts2026-07-12: 2 posts2026-07-13: 8 posts2026-07-14: 12 posts2026-07-15: 3 posts2026-07-16: 13 posts44+3%
Price updated 6h ago·X counts updated 1d ago
HYHYFT
$HYFTMindWalk Holdings Corp.
$1.46+3.55%44 posts+3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $HYFT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeWinding up for a moveAI verdict · as of 2026-07-16

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

AI-drug-discovery micro-cap sitting near the low end of the range with a July 22 print ahead.

MindWalk Holdings, formerly Hyfluence, is a $67 million biotech marketing itself as AI-driven drug discovery, and the tape is caught between a Russell 3000E inclusion in early July and a stock that still sits near the bottom of its fifty-two-week range.

  • Retail chatter compares the company to AMD or Micron as foundational infrastructure for biological AI, but revenue is negligible and the pipeline is preclinical, so today's story is about capital raises and hype cycles more than validated assets.
  • A recently filed patent on high-dimensional biological data architecture is the closest thing to a technical moat, and the July 22 fourth-quarter print is the first chance for management to attach numbers to the AI-drug-discovery narrative.
  • With a market cap under $100 million and a share price near $1.50, dilution risk is meaningful and any adverse commentary on cash runway would compress the multiple quickly.

Watch cash burn and runway on the fiscal-year print, any concrete partnership announcements, and dilution disclosures in the next filing.

Agrees with X sentimentBullish narrative chatter is directionally aligned but front-runs any operating validation.

What to watch: Cash runway, any biopharma partnership disclosures, and share-count movement in the FY filing.

On the calendar: Fourth-quarter and full-year results on July 22, 2026.

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-17

Posts highlight MindWalk Holdings' bio-native AI platform and recent wins in dengue and infectious-disease drug discovery via LensAI. Holders describe writing up deep dives and adding around $1.40, positioning it as an under-covered AI-in-healthcare story. Broader framing points to context-cost efficiency in AI as an unappreciated edge.

Read the AI verdict + X sentiment for $HYFT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops bio-native AI integrating neuroscience and machine learning for brain-computer interface and mental health applications.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $HYFT.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $HYFT

Neutral — Develops bio-native AI integrating neuroscience and machine learning for brain-computer interface and mental health applications; this business's revenue is largely decoupled from the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-63.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-65.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-10.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-63.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
60.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q4 2025Mar 12, 2026$-0.06$-0.04-50.0%
Q3 2025Dec 15, 2025$-0.05$-0.04-40.2%
Q2 2025Sep 15, 2025$-0.07$-0.04-75.0%
Q2 2025Jul 29, 2025$-0.04$-0.02-100.0%
Next earningsWed, Jul 22·consensus EPS $-0.05

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q3 FY26$4.1M-33.5%59.3%-88.4%$-0.08$-3.0M
Q2 FY26$4.1M+53.9%64.5%-67.0%$-0.07$-2.9M
Q1 FY26$3.2M+27.8%48.3%-131%$-0.07$-4.5M
Q4 FY25$7.0M+8.1%63.9%-20.9%$-0.06$-1.5M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$15.9M$15.9M – $15.9M-$0.31-$0.31 – -$0.312
FY27$19.6M$19.6M – $19.6M-$0.24-$0.24 – -$0.241
FY28$25.2M$24.7M – $25.8M-$0.16-$0.18 – -$0.142
FY29$31.5M$30.8M – $32.2M-$0.06-$0.10 – -$0.022
FY30$38.4M$38.4M – $38.5M$0.05$0.05 – $0.051

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.21%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-4.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-7.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 45.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.835-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 17 other (15 6-Ks · 1 F-3 · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026gurufocus.com·5d agoMindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026businesswire.com·5d agoMindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunitygurufocus.com·12d agoMindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunitybusinesswire.com·12d agoMindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discoverybusinesswire.com·17d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$RXRX
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport